Skip to content

Chinese cohort study of cerebral hemorrhage

Chinese cohort study of cerebral hemorrhage

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084436
Enrollment
Unknown
Registered
2024-05-16
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral hemorrhage

Interventions

Cerebral hemorrhage patients group:None
Healthy control group:None

Sponsors

Xiangya Hospital Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1: Ages 18 and above 2: Confirmation of intracerebral hemorrhage by head CT and/or MRI 3: Deep intracerebral hemorrhage (including the deep cerebral tissue regions such as the subcortical zone, lateral ventricular wall, and the radiate cortex), cerebral lobe hemorrhage (cerebral cortex, cortico-subcortical junction), cerebellar hemorrhage, and brainstem hemorrhage 4: Patients with intracerebral hemorrhage within 30 days of onset (including 30 days) who have been hospitalized 5: Informed consent and general informed consent signed by the patient and family members.

Exclusion criteria

Exclusion criteria: 1: Traumatic intracerebral hemorrhage 2: Secondary intracerebral hemorrhage (caused by cerebral aneurysm, large arteriovenous malformation, smoking disease, cavernous malformation, cerebral hemangioma, hematological disorders, thromboembolic stroke, vasculitis, cerebral venous thrombosis, post-ischemic hemorrhage transformation, history of anticoagulant or antiplatelet drug use, etc.) 3: Mixed intracerebral hemorrhage (involving multiple deep and cerebral lobe hemorrhages at the onset of the disease) 4: Coexisting psychiatric disorders, renal and hepatic failure, autoimmune diseases, malignant tumors, and pregnancy 5: Other investigators deemed ineligible for enrollment.

Design outcomes

Primary

MeasureTime frame
Neurofunctional prognosis;

Secondary

MeasureTime frame
Risk factor control;Compliance of recommended secondary medications;Symptomatic intracerebral hemorrhage recurrence events;All-cause mortality events;

Countries

China

Contacts

Public ContactZhangele

Xiangya Hospital, Central South University, Kaifu District, Changsha City, Hunan Province

zlzdzlzd@163.com+86 139 7318 7150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026